Xvivo Perfusion ABXVIPF -1.32%91 PS Ratio is 10.28 as of Jun. 26, 2026, which is 42% below its 10-year median of 17.74. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 84.2% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Xvivo Perfusion AB's share price is $29.0011.
Xvivo Perfusion AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.82. Hence, Xvivo Perfusion AB's PS Ratio for today is 10.28.
The historical rank and industry rank for Xvivo Perfusion AB's PS Ratio or its related term are showing as below:
XVIPF'
s PS Ratio Range Over the Past 10 Years
Min: 6.38 Med: 17.74 Max: 59.77
Current: 9.56
During the past 13 years, Xvivo Perfusion AB's highest PS Ratio was 59.77. The lowest was 6.38. And the median was 17.74.
XVIPF's PS Ratio is ranked worse than 84.2% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs XVIPF: 9.56
Xvivo Perfusion AB revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Xvivo Perfusion AB was -2.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 22.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 34.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 18.50% per year.
During the past 13 years, Xvivo Perfusion AB's highest 3-Year average Revenue per Share Growth Rate was 44.80% per year. The lowest was 4.40% per year. And the median was 15.85% per year.
Back to Basics: PS Ratio
Xvivo Perfusion AB (OTCPK:XVIPF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Xvivo Perfusion AB PS Ratio Related Terms
Xvivo Perfusion AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Xvivo Perfusion AB's Share Price of today is $29.0011. Xvivo Perfusion AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.82.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Xvivo Perfusion AB (XVIPF) has a PS Ratio of 10.28 as of Jun. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Xvivo Perfusion AB and its competitors. This is 42% below median its historical median of 17.74. Over the past decade, Xvivo Perfusion AB's PS Ratio has ranged from 6.38 to 59.77. According to the industry distribution chart, Xvivo Perfusion AB ranks #677 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 84.2%.
Is Xvivo Perfusion AB's PS Ratio too high?
Xvivo Perfusion AB's current PS Ratio of 10.28 is 42% below median its 10-year median of 17.74. Over the past 10 years, this metric has ranged from a low of 6.38 to a high of 59.77. The Medical Devices & Instruments industry median PS Ratio is 2.86. Xvivo Perfusion AB's value of 10.28 is 259.4% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #677 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #677 out of 804 companies for PS Ratio. This places Xvivo Perfusion AB in the lower half of its industry. The industry median PS Ratio is 2.86. Xvivo Perfusion AB's value of 10.28 is 259.4% above this benchmark. Historically, Xvivo Perfusion AB's own PS Ratio has ranged from 6.38 to 59.77 over the past decade. While the company's 10-year median is 17.74 vs. the industry median of 2.86, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current PS Ratio of 10.28 is 259.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current PS Ratio is 10.28, which is 42% below median its own 10-year median of 17.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current PS Ratio is 10.28, which is 42% below median its 10-year median of 17.74 and 259.4% above the Medical Devices & Instruments industry median of 2.86. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current PS Ratio is 10.28 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
PS Ratio: 10.28 (42% below median its 10-year median of 17.74)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 259.4% above the Medical Devices & Instruments median (#677 of 804)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
